<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01116024</url>
  </required_header>
  <id_info>
    <org_study_id>S2005 Rev. 17-MAY-2007</org_study_id>
    <nct_id>NCT01116024</nct_id>
  </id_info>
  <brief_title>ATS 3f Enable(tm) Aortic Bioprosthesis, Model 6000</brief_title>
  <acronym>Enable</acronym>
  <official_title>ATS 3f Enable(tm) Aortic Bioprosthesis, Model 6000</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medtronic Cardiovascular</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Medtronic Cardiovascular</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a prospective, non-randomized, multi-center study designed to evaluate safety and
      effectiveness of the ATS 3f Enable Aortic Bioprosthesis in a patient population undergoing
      isolated aortic valve replacement with or without concomitant procedures. The Enable Aortic
      Valve is an equine pericardial stented bioprosthesis.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The ATS 3f Enable Aortic Bioprosthesis is intended for those patients whose prognosis without
      surgical replacement of the diseased natural valve is unacceptably poor in terms of survival
      and/or quality of life in the opinion of the attending physicians. For these patients, there
      are a number of widely accepted prosthetic heart valves in use.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2006</start_date>
  <completion_date type="Actual">August 2012</completion_date>
  <primary_completion_date type="Actual">December 2010</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Thromboembolism/Thrombosis</measure>
    <time_frame>Five Years</time_frame>
    <description>Valve related thromboembolism and valvular thrombosis.
Thrombosis was defined as any thrombus attached to or near the study valve that interfered with valve function in the absence of infection. The results are reported as linearized rate (percentage of participants per patient-year)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Hemorrhage/Bleeding-Anticoagulant/Antiaggregant (All and Major)</measure>
    <time_frame>Five Years</time_frame>
    <description>Any episode of internal or external bleeding in subjects receiving anticoagulant and/or antiaggregant therapy.
Hemorrhage/Bleeding (No Anticoagulant/Antiaggregant):
Any episode of internal or external bleeding in subjects not receiving anticoagulant and/or antiaggregant therapy.
The results are reported as linearized rate (percentage of participants per patient-year).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Paravalvular Leaks (All and Major)</measure>
    <time_frame>Five Years</time_frame>
    <description>Paravalvular leak was defined as any evidence of leakage of blood around the prosthesis (between the sewing ring and native annulus). Major Paravalvular leak was defined as any evidence of leakage of blood around the prosthesis, i.e. between the sewing ring and native annulus that requires surgical intervention.
The results are reported as linearized rate (percentage of participants per patient-year).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Endocarditis</measure>
    <time_frame>Five Years</time_frame>
    <description>Endocarditis was defined in the protocol as any infection involving the study valve. Any structural/non-structural valvular dysfunction, thrombosis, or embolic event associated with study valve endocarditis was captured as endocarditis only.
The results are reported as linearized rate (percentage of participants per patient-year).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Hemolysis</measure>
    <time_frame>Five Years</time_frame>
    <description>Blood data analysis was performed in order to identify whether particular complications and serious adverse events such as hemolysis occurred. Hemolysis in subjects with tissue valves - as evidenced by increased serum lactate dehydrogenase concentrations, decreased serum haptoglobin concentration, erythrocytopenia and reticulocytosis - is usually associated with paravalvular leakage or infection.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Structural Valve Deterioration</measure>
    <time_frame>Five Years</time_frame>
    <description>Structural deterioration was defined as any change in the study valve function which resulted from an intrinsic abnormality that caused stenosis or regurgitation.
There were no cases of structural deterioration reported for the study.
The results are reported as linearized rate (percentage of participants per patient-year).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Non-Structural Dysfunction</measure>
    <time_frame>Five Years</time_frame>
    <description>Any abnormality resulting in stenosis or regurgitation at the operated valve that is not intrinsic to the valve itself. Non-structural dysfunction refers to non-structural problems that result in dysfunction of an operated valve exclusive of thrombosis and infection diagnosed by reoperation, autopsy, or clinical investigation.
The results are reported as linearized rate (percentage of participants per patient-year).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Re-operation, Explant, Repair</measure>
    <time_frame>Five Years</time_frame>
    <description>Reoperation was defined in the protocol as any operation to repair, alter, or replace the study valve. Included is reoperation for repair of paravalvular leak and explant.
The results are reported as linearized rate (percentage of participants per patient-year).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Effectiveness Endpoint - NYHA Classification, Hemodynamic Performance</measure>
    <time_frame>Five Years</time_frame>
    <description>New York Heart Association (NYHA) classification to asses improvement of the cardiac status, Hemodynamic Performance analysis based on Doppler echocardiographic studies.
Class I: Patients with cardiac disease but without limitations of ordinary activity.
Class II: Patients with cardiac disease resulting in slight limitation of physical activity. Comfortable at rest. Ordinary physical activity results in fatigue, palpitation, dyspnea or anginal pain.
Class III: Patients with cardiac disease resulting in marked limitation of physical activity. They are comfortable at rest. Less than ordinary physical activity results in fatigue, palpitations or anginal pain.
Class IV: Patients with cardiac disease resulting in inability to carry out any physical activity without discomfort. Symptoms of cardiac insufficiency or anginal syndrome may be present even at rest. If any physical activity is undertaken discomfort is increased.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Hemodynamic</measure>
    <time_frame>Five Years</time_frame>
    <description>Mean and peak pressure gradients from discharge through 5 years follow up. The gradient represents the difference in blood pressure across the valve.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Hemodynamics - Effective Orifice Area</measure>
    <time_frame>Five Years</time_frame>
    <description>Effective orifice area (EOA) data.
The effective orifice area is a measure of how much the heart valve prosthesis impedes blood flow through the aortic valve.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Hemodynamics - Effective Orifice Area Index</measure>
    <time_frame>Five Years</time_frame>
    <description>The effective orifice area index is a measure of how much the heart valve prosthesis impedes blood flow through the aortic valve.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">173</enrollment>
  <condition>Heart Valve Diseases</condition>
  <arm_group>
    <arm_group_label>3f Enable Aortic Bioprosthesis Model 6000</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single arm study</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>ATS 3f Enable Aortic Bioprosthesis Model 6000</intervention_name>
    <description>Replacement Aortic Heart Valve</description>
    <arm_group_label>3f Enable Aortic Bioprosthesis Model 6000</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  The patient requires isolated aortic valve replacement with or without concomitant
             procedures such as coronary artery bypass or another valve repair. (The three
             remaining valves must be of native tissue).

          -  The patient is geographically stable and willing to return to the implant site for
             follow-up visits.

          -  The patient has been adequately informed of risks and requirements and consent to
             his/her participation in the clinical study.

          -  If this patient is female and of childbearing potential, patient has a negative
             pregnancy test within seven (7) days prior to the study procedure.

        Exclusion Criteria:

          -  The patient requires replacement of two or more valves.

          -  The patient is &lt; 20 years of age.

          -  The patient has a non-cardiac major or progressive disease, which in the
             Investigator's experience produces an unacceptable increased risk to the patient, or
             results in a life expectancy of less than 24 months.

          -  The patient is an intravenous drug and/or alcohol abuser.

          -  The patient presents with active endocarditis or other systemic infection.

          -  The patient has had previous valve replacement surgery, including previous implant and
             then explant of the ATS 3f Enable Aortic Bioprosthesis (Model 6000) or placement of a
             rigid annuloplasty ring in the mitral position.

          -  The patient is participating in concomitant research studies of investigational
             products.

          -  The patient presents with dilatation of the ascending aorta, Marfan Syndrome,
             Ehlers-Danlos syndrome, cystic medial degeneration, or other condition causing the
             ascending aorta to be irregular in geometry or physiology as seen via preoperative
             imaging.

          -  The patient has chronic renal failure.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Eric Vang</last_name>
    <role>Study Director</role>
    <affiliation>Medtronic</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Medical University of Vienna</name>
      <address>
        <city>Vienna</city>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Johann Wolfgang Goethe University</name>
      <address>
        <city>Frankfurt</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Medical Center Freiburg</name>
      <address>
        <city>Freiburg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Medical Center Kiel</name>
      <address>
        <city>Kiel</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UKSH, Campus Lubeck</name>
      <address>
        <city>Lubeck</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical University of Gdansk</name>
      <address>
        <city>Gdansk</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Jagiellonian University</name>
      <address>
        <city>Krakow</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cardiac Surgery University Hospital Basel</name>
      <address>
        <city>Basel</city>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Inselspital Bern</name>
      <address>
        <city>Bern</city>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>John Radcliffe Hospital</name>
      <address>
        <city>Oxford</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Austria</country>
    <country>Germany</country>
    <country>Poland</country>
    <country>Switzerland</country>
    <country>United Kingdom</country>
  </location_countries>
  <link>
    <url>http://www.medtronic.com/</url>
    <description>Medtronic, Inc. Corporate Website</description>
  </link>
  <verification_date>October 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 8, 2010</study_first_submitted>
  <study_first_submitted_qc>May 3, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 4, 2010</study_first_posted>
  <results_first_submitted>May 26, 2016</results_first_submitted>
  <results_first_submitted_qc>October 12, 2016</results_first_submitted_qc>
  <results_first_posted type="Estimate">December 5, 2016</results_first_posted>
  <last_update_submitted>November 20, 2017</last_update_submitted>
  <last_update_submitted_qc>November 20, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">December 19, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Diseased Heart Valve, Replacement, Aortic</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Valve Diseases</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>Patients who required an aortic valve replacement were considered for this study if they met all study preoperative selection criteria.
Enrollment for this study was closed at 173 subjects following the receipt of Conformité Européenne (CE) Mark.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>ATS 3f Enable Aortic Bioprosthesis Model 6000</title>
          <description>ATS 3f Enable Aortic Bioprosthesis Model 6000 : Replacement Aortic Heart Valve</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="148">Patient Enrollment start date</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="96">Patient Enrollment stop date</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="52"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>173 subjects were enrolled in the study. Of the 173 subjects enrolled, a cohort of 148 subjects were implanted with, and left the operating room with, the Model 6000 valve. As per protocol, only subjects who left the operating room with the device implanted were followed and included in the analysis.</population>
      <group_list>
        <group group_id="B1">
          <title>Aortic Valve Replacement</title>
          <description>3f Enable Aortic Bioprosthesis Model 6000</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="148"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="76.0" spread="5.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="91"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Austria</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Poland</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>United Kingdom</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Switzerland</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Germany</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Thromboembolism/Thrombosis</title>
        <description>Valve related thromboembolism and valvular thrombosis.
Thrombosis was defined as any thrombus attached to or near the study valve that interfered with valve function in the absence of infection. The results are reported as linearized rate (percentage of participants per patient-year)</description>
        <time_frame>Five Years</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Enable I Model 6000 Valve: Replacement Aortic Heart Valve</title>
            <description>Study is single-arm. All subjects analyzed received the Enable I Model 6000 Valve.</description>
          </group>
        </group_list>
        <measure>
          <title>Thromboembolism/Thrombosis</title>
          <description>Valve related thromboembolism and valvular thrombosis.
Thrombosis was defined as any thrombus attached to or near the study valve that interfered with valve function in the absence of infection. The results are reported as linearized rate (percentage of participants per patient-year)</description>
          <units>percentage of participants/patient-year</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="148"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Late Thromboembolism</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" lower_limit="0" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Non-Structural Valve Dysfunction</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.7" lower_limit="1.4" upper_limit="5.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>All PVL</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.4" lower_limit="1.2" upper_limit="4.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Major Paravalvular Leak</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.5" lower_limit="0.6" upper_limit="3.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Thrombosis</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" lower_limit="0" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Hemorrhage/Bleeding-Anticoagulant/Antiaggregant (All and Major)</title>
        <description>Any episode of internal or external bleeding in subjects receiving anticoagulant and/or antiaggregant therapy.
Hemorrhage/Bleeding (No Anticoagulant/Antiaggregant):
Any episode of internal or external bleeding in subjects not receiving anticoagulant and/or antiaggregant therapy.
The results are reported as linearized rate (percentage of participants per patient-year).</description>
        <time_frame>Five Years</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Enable I Model 6000 Valve</title>
            <description>Study is single-arm. All subjects analyzed received the Enable I Model 6000 Valve.</description>
          </group>
        </group_list>
        <measure>
          <title>Hemorrhage/Bleeding-Anticoagulant/Antiaggregant (All and Major)</title>
          <description>Any episode of internal or external bleeding in subjects receiving anticoagulant and/or antiaggregant therapy.
Hemorrhage/Bleeding (No Anticoagulant/Antiaggregant):
Any episode of internal or external bleeding in subjects not receiving anticoagulant and/or antiaggregant therapy.
The results are reported as linearized rate (percentage of participants per patient-year).</description>
          <units>percentage of participants/patient-year</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="148"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>All Hemorrhage Bleeding</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.5" lower_limit="0.6" upper_limit="3.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Major Hemorrhage</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.5" lower_limit="0.6" upper_limit="3.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Major Hemorrhage Bleeding Anticoagulant</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.9" lower_limit="0.3" upper_limit="2.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Major Hemorrhage Bleeding No Anticoagulant</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.6" lower_limit="0.1" upper_limit="2.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Paravalvular Leaks (All and Major)</title>
        <description>Paravalvular leak was defined as any evidence of leakage of blood around the prosthesis (between the sewing ring and native annulus). Major Paravalvular leak was defined as any evidence of leakage of blood around the prosthesis, i.e. between the sewing ring and native annulus that requires surgical intervention.
The results are reported as linearized rate (percentage of participants per patient-year).</description>
        <time_frame>Five Years</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Enable I Model 6000 Valve</title>
            <description>Study is single-arm. All subjects analyzed received the Enable I Model 6000 Valve.</description>
          </group>
        </group_list>
        <measure>
          <title>Paravalvular Leaks (All and Major)</title>
          <description>Paravalvular leak was defined as any evidence of leakage of blood around the prosthesis (between the sewing ring and native annulus). Major Paravalvular leak was defined as any evidence of leakage of blood around the prosthesis, i.e. between the sewing ring and native annulus that requires surgical intervention.
The results are reported as linearized rate (percentage of participants per patient-year).</description>
          <units>percentage of participants/patient-year</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="148"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>All paravalvular leak</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.4" lower_limit="1.2" upper_limit="4.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Major paravalvular leak</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.5" lower_limit="0.6" upper_limit="3.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Endocarditis</title>
        <description>Endocarditis was defined in the protocol as any infection involving the study valve. Any structural/non-structural valvular dysfunction, thrombosis, or embolic event associated with study valve endocarditis was captured as endocarditis only.
The results are reported as linearized rate (percentage of participants per patient-year).</description>
        <time_frame>Five Years</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Enable I Model 6000 Valve: Replacement Aortic Heart Valve</title>
            <description>Study is single-arm. All subjects analyzed received the Enable I Model 6000 Valve.</description>
          </group>
        </group_list>
        <measure>
          <title>Endocarditis</title>
          <description>Endocarditis was defined in the protocol as any infection involving the study valve. Any structural/non-structural valvular dysfunction, thrombosis, or embolic event associated with study valve endocarditis was captured as endocarditis only.
The results are reported as linearized rate (percentage of participants per patient-year).</description>
          <units>percentage of participants/patient-year</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="148"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.9" lower_limit="0.3" upper_limit="2.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Hemolysis</title>
        <description>Blood data analysis was performed in order to identify whether particular complications and serious adverse events such as hemolysis occurred. Hemolysis in subjects with tissue valves – as evidenced by increased serum lactate dehydrogenase concentrations, decreased serum haptoglobin concentration, erythrocytopenia and reticulocytosis – is usually associated with paravalvular leakage or infection.</description>
        <time_frame>Five Years</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Enable I Model 6000 Valve: Replacement Aortic Heart Valve</title>
            <description>Study is single-arm. All subjects analyzed received the Enable I Model 6000 Valve.</description>
          </group>
        </group_list>
        <measure>
          <title>Hemolysis</title>
          <description>Blood data analysis was performed in order to identify whether particular complications and serious adverse events such as hemolysis occurred. Hemolysis in subjects with tissue valves – as evidenced by increased serum lactate dehydrogenase concentrations, decreased serum haptoglobin concentration, erythrocytopenia and reticulocytosis – is usually associated with paravalvular leakage or infection.</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="148"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Structural Valve Deterioration</title>
        <description>Structural deterioration was defined as any change in the study valve function which resulted from an intrinsic abnormality that caused stenosis or regurgitation.
There were no cases of structural deterioration reported for the study.
The results are reported as linearized rate (percentage of participants per patient-year).</description>
        <time_frame>Five Years</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Enable I Model 6000 Valve: Replacement Aortic Heart Valve</title>
            <description>Study is single-arm. All subjects analyzed received the Enable I Model 6000 Valve.</description>
          </group>
        </group_list>
        <measure>
          <title>Structural Valve Deterioration</title>
          <description>Structural deterioration was defined as any change in the study valve function which resulted from an intrinsic abnormality that caused stenosis or regurgitation.
There were no cases of structural deterioration reported for the study.
The results are reported as linearized rate (percentage of participants per patient-year).</description>
          <units>percentage of participants/patient-year</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="148"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Non-Structural Dysfunction</title>
        <description>Any abnormality resulting in stenosis or regurgitation at the operated valve that is not intrinsic to the valve itself. Non-structural dysfunction refers to non-structural problems that result in dysfunction of an operated valve exclusive of thrombosis and infection diagnosed by reoperation, autopsy, or clinical investigation.
The results are reported as linearized rate (percentage of participants per patient-year).</description>
        <time_frame>Five Years</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Enable I Model 6000 Valve: Replacement Aortic Heart Valve</title>
            <description>Study is single-arm. All subjects analyzed received the Enable I Model 6000 Valve.</description>
          </group>
        </group_list>
        <measure>
          <title>Non-Structural Dysfunction</title>
          <description>Any abnormality resulting in stenosis or regurgitation at the operated valve that is not intrinsic to the valve itself. Non-structural dysfunction refers to non-structural problems that result in dysfunction of an operated valve exclusive of thrombosis and infection diagnosed by reoperation, autopsy, or clinical investigation.
The results are reported as linearized rate (percentage of participants per patient-year).</description>
          <units>percentage of participants/patient-year</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="148"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.7" lower_limit="1.4" upper_limit="5.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Re-operation, Explant, Repair</title>
        <description>Reoperation was defined in the protocol as any operation to repair, alter, or replace the study valve. Included is reoperation for repair of paravalvular leak and explant.
The results are reported as linearized rate (percentage of participants per patient-year).</description>
        <time_frame>Five Years</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Enable I Model 6000 Valve: Replacement Aortic Heart Valve</title>
            <description>Study is single-arm. All subjects analyzed received the Enable I Model 6000 Valve.</description>
          </group>
        </group_list>
        <measure>
          <title>Re-operation, Explant, Repair</title>
          <description>Reoperation was defined in the protocol as any operation to repair, alter, or replace the study valve. Included is reoperation for repair of paravalvular leak and explant.
The results are reported as linearized rate (percentage of participants per patient-year).</description>
          <units>percentage of participants/patient-year</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="148"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Reoperation (All)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.1" lower_limit="1.0" upper_limit="4.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Explant</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.1" lower_limit="1.0" upper_limit="4.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Repair</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" lower_limit="0" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Effectiveness Endpoint - NYHA Classification, Hemodynamic Performance</title>
        <description>New York Heart Association (NYHA) classification to asses improvement of the cardiac status, Hemodynamic Performance analysis based on Doppler echocardiographic studies.
Class I: Patients with cardiac disease but without limitations of ordinary activity.
Class II: Patients with cardiac disease resulting in slight limitation of physical activity. Comfortable at rest. Ordinary physical activity results in fatigue, palpitation, dyspnea or anginal pain.
Class III: Patients with cardiac disease resulting in marked limitation of physical activity. They are comfortable at rest. Less than ordinary physical activity results in fatigue, palpitations or anginal pain.
Class IV: Patients with cardiac disease resulting in inability to carry out any physical activity without discomfort. Symptoms of cardiac insufficiency or anginal syndrome may be present even at rest. If any physical activity is undertaken discomfort is increased.</description>
        <time_frame>Five Years</time_frame>
        <group_list>
          <group group_id="O1">
            <title>NYHA Class Preoperative</title>
            <description>Preoperative numbers of NYHA classification.</description>
          </group>
          <group group_id="O2">
            <title>NYHA Class 3-6 Months</title>
            <description>NYHA classification after 3-6 months.</description>
          </group>
          <group group_id="O3">
            <title>NYHA Class 11-14 Months</title>
            <description>NYHA classification after 11-14 months.</description>
          </group>
          <group group_id="O4">
            <title>NYHA Class 2 Year</title>
            <description>NYHA classification after 2 years.</description>
          </group>
          <group group_id="O5">
            <title>NYHA Class 3 Year</title>
            <description>NYHA classification after 3 years.</description>
          </group>
          <group group_id="O6">
            <title>NYHA Class 4 Year</title>
            <description>NYHA classification after 4 years.</description>
          </group>
          <group group_id="O7">
            <title>NYHA Class 5 Year</title>
            <description>NYHA classification after 5 years.</description>
          </group>
        </group_list>
        <measure>
          <title>Effectiveness Endpoint - NYHA Classification, Hemodynamic Performance</title>
          <description>New York Heart Association (NYHA) classification to asses improvement of the cardiac status, Hemodynamic Performance analysis based on Doppler echocardiographic studies.
Class I: Patients with cardiac disease but without limitations of ordinary activity.
Class II: Patients with cardiac disease resulting in slight limitation of physical activity. Comfortable at rest. Ordinary physical activity results in fatigue, palpitation, dyspnea or anginal pain.
Class III: Patients with cardiac disease resulting in marked limitation of physical activity. They are comfortable at rest. Less than ordinary physical activity results in fatigue, palpitations or anginal pain.
Class IV: Patients with cardiac disease resulting in inability to carry out any physical activity without discomfort. Symptoms of cardiac insufficiency or anginal syndrome may be present even at rest. If any physical activity is undertaken discomfort is increased.</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="148"/>
                <count group_id="O2" value="119"/>
                <count group_id="O3" value="109"/>
                <count group_id="O4" value="93"/>
                <count group_id="O5" value="71"/>
                <count group_id="O6" value="32"/>
                <count group_id="O7" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Class I</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                    <measurement group_id="O2" value="47"/>
                    <measurement group_id="O3" value="51"/>
                    <measurement group_id="O4" value="41"/>
                    <measurement group_id="O5" value="37"/>
                    <measurement group_id="O6" value="10"/>
                    <measurement group_id="O7" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Class II</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="38"/>
                    <measurement group_id="O2" value="61"/>
                    <measurement group_id="O3" value="53"/>
                    <measurement group_id="O4" value="48"/>
                    <measurement group_id="O5" value="29"/>
                    <measurement group_id="O6" value="19"/>
                    <measurement group_id="O7" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Class III</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="92"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="4"/>
                    <measurement group_id="O4" value="4"/>
                    <measurement group_id="O5" value="5"/>
                    <measurement group_id="O6" value="3"/>
                    <measurement group_id="O7" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Class IV</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unknown</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="7"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Hemodynamic</title>
        <description>Mean and peak pressure gradients from discharge through 5 years follow up. The gradient represents the difference in blood pressure across the valve.</description>
        <time_frame>Five Years</time_frame>
        <population>At discharge, gradient data was collected of 103 subjects.</population>
        <group_list>
          <group group_id="O1">
            <title>Discharge</title>
            <description>Gradient at discharge</description>
          </group>
          <group group_id="O2">
            <title>3-6 Months</title>
            <description>Gradient at 3-6 Months</description>
          </group>
          <group group_id="O3">
            <title>11-14 Months</title>
            <description>Gradient at 11-14 months</description>
          </group>
          <group group_id="O4">
            <title>2 Years</title>
            <description>Gradient at 2 Years</description>
          </group>
          <group group_id="O5">
            <title>3 Years</title>
            <description>Gradient at 3 Years</description>
          </group>
          <group group_id="O6">
            <title>4 Years</title>
            <description>Gradient at 4 Years</description>
          </group>
          <group group_id="O7">
            <title>5 Years</title>
            <description>Gradient at 5 Years</description>
          </group>
        </group_list>
        <measure>
          <title>Hemodynamic</title>
          <description>Mean and peak pressure gradients from discharge through 5 years follow up. The gradient represents the difference in blood pressure across the valve.</description>
          <population>At discharge, gradient data was collected of 103 subjects.</population>
          <units>mmHg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="103"/>
                <count group_id="O2" value="98"/>
                <count group_id="O3" value="89"/>
                <count group_id="O4" value="74"/>
                <count group_id="O5" value="62"/>
                <count group_id="O6" value="42"/>
                <count group_id="O7" value="2"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Mean Gradient</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.28" spread="4.37"/>
                    <measurement group_id="O2" value="9.02" spread="3.70"/>
                    <measurement group_id="O3" value="8.59" spread="3.19"/>
                    <measurement group_id="O4" value="8.52" spread="3.39"/>
                    <measurement group_id="O5" value="8.77" spread="4.37"/>
                    <measurement group_id="O6" value="8.53" spread="4.79"/>
                    <measurement group_id="O7" value="5.55" spread="1.20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Peak Gradient</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20.38" spread="8.40"/>
                    <measurement group_id="O2" value="18.15" spread="7.17"/>
                    <measurement group_id="O3" value="16.58" spread="6.16"/>
                    <measurement group_id="O4" value="16.65" spread="6.89"/>
                    <measurement group_id="O5" value="17.69" spread="8.77"/>
                    <measurement group_id="O6" value="17.04" spread="8.75"/>
                    <measurement group_id="O7" value="10.30" spread="3.54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Hemodynamics - Effective Orifice Area</title>
        <description>Effective orifice area (EOA) data.
The effective orifice area is a measure of how much the heart valve prosthesis impedes blood flow through the aortic valve.</description>
        <time_frame>Five Years</time_frame>
        <population>At discharge Effective Orifice Area data was collected for 61 subjects.</population>
        <group_list>
          <group group_id="O1">
            <title>Discharge</title>
            <description>Effective Orifice Area at discharge</description>
          </group>
          <group group_id="O2">
            <title>3-6 Months</title>
            <description>Effective Orifice Area at 3-6 months</description>
          </group>
          <group group_id="O3">
            <title>11-14 Months</title>
            <description>Effective Orifice Area at 11-14 months</description>
          </group>
          <group group_id="O4">
            <title>2 Years</title>
            <description>Effective Orifice Area at 2 years</description>
          </group>
          <group group_id="O5">
            <title>3 Years</title>
            <description>Effective Orifice Area at 3 years</description>
          </group>
          <group group_id="O6">
            <title>4 Years</title>
            <description>Effective Orifice Area at 4 years</description>
          </group>
          <group group_id="O7">
            <title>5 Years</title>
            <description>Effective Orifice Area at 5 years</description>
          </group>
        </group_list>
        <measure>
          <title>Hemodynamics - Effective Orifice Area</title>
          <description>Effective orifice area (EOA) data.
The effective orifice area is a measure of how much the heart valve prosthesis impedes blood flow through the aortic valve.</description>
          <population>At discharge Effective Orifice Area data was collected for 61 subjects.</population>
          <units>EOA (cm2)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="61"/>
                <count group_id="O2" value="73"/>
                <count group_id="O3" value="66"/>
                <count group_id="O4" value="51"/>
                <count group_id="O5" value="44"/>
                <count group_id="O6" value="34"/>
                <count group_id="O7" value="2"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.71" spread="0.45"/>
                    <measurement group_id="O2" value="1.68" spread="0.51"/>
                    <measurement group_id="O3" value="1.70" spread="0.46"/>
                    <measurement group_id="O4" value="1.66" spread="0.47"/>
                    <measurement group_id="O5" value="1.67" spread="0.43"/>
                    <measurement group_id="O6" value="1.62" spread="0.41"/>
                    <measurement group_id="O7" value="1.75" spread="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Hemodynamics - Effective Orifice Area Index</title>
        <description>The effective orifice area index is a measure of how much the heart valve prosthesis impedes blood flow through the aortic valve.</description>
        <time_frame>Five Years</time_frame>
        <population>At discharge Effective Orifice Area index data was collected for 61 subjects.</population>
        <group_list>
          <group group_id="O1">
            <title>Discharge</title>
            <description>Effective Orifice Area at discharge</description>
          </group>
          <group group_id="O2">
            <title>3-6 Months</title>
            <description>Effective Orifice Area at 3-6 months</description>
          </group>
          <group group_id="O3">
            <title>11-14 Months</title>
            <description>Effective Orifice Area at 11-14 months</description>
          </group>
          <group group_id="O4">
            <title>2 Years</title>
            <description>Effective Orifice Area at 2 years</description>
          </group>
          <group group_id="O5">
            <title>3 Years</title>
            <description>Effective Orifice Area at 3 years</description>
          </group>
          <group group_id="O6">
            <title>4 Years</title>
            <description>Effective Orifice Area at 4 years</description>
          </group>
          <group group_id="O7">
            <title>5 Years</title>
            <description>Effective Orifice Area at 5 years</description>
          </group>
        </group_list>
        <measure>
          <title>Hemodynamics - Effective Orifice Area Index</title>
          <description>The effective orifice area index is a measure of how much the heart valve prosthesis impedes blood flow through the aortic valve.</description>
          <population>At discharge Effective Orifice Area index data was collected for 61 subjects.</population>
          <units>EOAi (cm2/m2)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="61"/>
                <count group_id="O2" value="73"/>
                <count group_id="O3" value="66"/>
                <count group_id="O4" value="51"/>
                <count group_id="O5" value="44"/>
                <count group_id="O6" value="34"/>
                <count group_id="O7" value="2"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.94" spread="0.25"/>
                    <measurement group_id="O2" value="0.91" spread="0.27"/>
                    <measurement group_id="O3" value="0.93" spread="0.25"/>
                    <measurement group_id="O4" value="0.89" spread="0.25"/>
                    <measurement group_id="O5" value="0.92" spread="0.25"/>
                    <measurement group_id="O6" value="0.89" spread="0.24"/>
                    <measurement group_id="O7" value="1.03" spread="0.06"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>5 Years</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Enable I Model 6000 Valve</title>
          <description>Adverse events relating to the study safety endpoints.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>Valve-Related</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="39" subjects_at_risk="148"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Valve-Related Adverse Event</sub_title>
                <description>Seventeen out of 148 subjects (11.5%) experienced a Paravalvular Leak (PVL). Of these seventeen PVLs, nine events were reported as minor PVLs and eight events were reported as major PVLs. Three out of the 148 subjects (2.0%) developed endocarditis.</description>
                <counts group_id="E1" events="19" subjects_affected="19" subjects_at_risk="148"/>
              </event>
              <event>
                <sub_title vocab="Not-Valve Related">Not Valve-Related Adverse Event</sub_title>
                <description>Five of the hemorrhage events were early events and three were late events.</description>
                <counts group_id="E1" events="17" subjects_affected="17" subjects_at_risk="148"/>
              </event>
              <event>
                <sub_title vocab="Unknown ValveRelated">Unknown Valve-Relatedness Adverse Event</sub_title>
                <description>One out of the 148 subjects (0.7%) implanted experienced an early thromboembolism with a 21 mm valve. This subject experienced a peripheral arterial event, reported as unknown valve relatedness which resolved without permanent sequelae.</description>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="148"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>Unknown ValveRelated</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="148"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Unknown Valve Relatedness Adverse Event</sub_title>
                <description>Unknown Valve Relatedness Adverse Event</description>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="148"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Of the 173 subjects enrolled, a cohort of 148 subjects were implanted, followed and included in the analysis. 25 of the 173 subjects enrolled were intraoperative exclusions due to surgeon’s discretion during the operative thoracotomy.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Ryan Palmer, Principal Clinical Research Specialist</name_or_title>
      <organization>Medtronic, Inc.</organization>
      <phone>763-514-9732 ext 49732</phone>
      <email>ryan.j.palmer@medtronic.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

